A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin

Background Access to direct-acting antiviral agents (DAAs) is restricted in some settings; thus, the Euro pean Association for the Study of the Liver recommends dual peginterferon/ribavirin (PegIFN/RBV) therapy wherever DAAs are unavailable. HCV genotype (GT) 3 infection is now the most difficult ge...

ver descrição completa

Detalhes bibliográficos
Autores: Asselah, Tarik, Thompson, Ale J., Flisiak, Robert, Romero Gómez, Manuel, Messinger, Diethelm, Bakalos, Georgios, Shiffman, Mitchell L.
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2016
País:España
Recursos:Universidad de Sevilla (US)
Repositorio:idUS. Depósito de Investigación de la Universidad de Sevilla
OAI Identifier:oai:idus.us.es:11441/108574
Acesso em linha:https://hdl.handle.net/11441/108574
https://doi.org/10.1371/journal.pone.0150569
Access Level:acceso abierto
Palavra-chave:HCV
Genotype 3
Peginterferon Alfa-2a/Ribavirin
id ES_9d7d1d1f5e25259eaebf8b616b5a19cd
oai_identifier_str oai:idus.us.es:11441/108574
network_acronym_str ES
network_name_str España
repository_id_str
spelling A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/RibavirinAsselah, TarikThompson, Ale J.Flisiak, RobertRomero Gómez, ManuelMessinger, DiethelmBakalos, GeorgiosShiffman, Mitchell L.HCVGenotype 3Peginterferon Alfa-2a/RibavirinBackground Access to direct-acting antiviral agents (DAAs) is restricted in some settings; thus, the Euro pean Association for the Study of the Liver recommends dual peginterferon/ribavirin (PegIFN/RBV) therapy wherever DAAs are unavailable. HCV genotype (GT) 3 infection is now the most difficult genotype to eradicate and PegIFN/RBV remains an effective option. The goal of this study was to devise a simple predictive score to identify GT3 patients with a high probability of achieving a sustained virologic response (SVR) with PegIFN alfa-2a/RBV therapy. Methods Relationships between baseline characteristics and SVR were explored by multiple logistic regression models and used to develop a simple scoring system to predict SVR using data from 1239 treatment-naive GT3 patients who received PegIFN alfa-2a/RBV for 24 weeks in two large observational cohort studies. Results The score was validated using a database of 473 patients. Scores were assigned for six fac tors as follows: age (years) ( 40: 2 points; >40 but 55: 1); bodyweight (kg) (<70: 2; 70 but <90: 1); no cirrhosis/transition to cirrhosis (2); ALT 2.5 x ULN (1); platelets (109 /L) (>200: 2; 100 but <200: 1); HCV RNA (<400,000 IU/mL: 1). The points are summed to arrive at a score ranging from 0-10 where higher scores indicate higher chances of SVR; 141, 123, 203, 249, 232, and 218 patients had total scores of 0-4, 5, 6, 7, 8, and 9–10, respectively, among whom SVR rates were 45%, 62%, 72%, 76%, 84%, and 89%. Among 622 patients who had scores of 6-10 and HCV RNA <50 IU/mL by treatment week 4 the SVR rate was 86% (532/622).Medicina2016info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttps://hdl.handle.net/11441/108574https://doi.org/10.1371/journal.pone.0150569reponame:idUS. Depósito de Investigación de la Universidad de Sevillainstname:Universidad de Sevilla (US)InglésPLoS ONE, 11 (3)info:eu-repo/semantics/openAccessoai:idus.us.es:11441/1085742026-06-17T12:51:07Z
dc.title.none.fl_str_mv A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin
title A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin
spellingShingle A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin
Asselah, Tarik
HCV
Genotype 3
Peginterferon Alfa-2a/Ribavirin
title_short A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin
title_full A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin
title_fullStr A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin
title_full_unstemmed A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin
title_sort A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin
dc.creator.none.fl_str_mv Asselah, Tarik
Thompson, Ale J.
Flisiak, Robert
Romero Gómez, Manuel
Messinger, Diethelm
Bakalos, Georgios
Shiffman, Mitchell L.
author Asselah, Tarik
author_facet Asselah, Tarik
Thompson, Ale J.
Flisiak, Robert
Romero Gómez, Manuel
Messinger, Diethelm
Bakalos, Georgios
Shiffman, Mitchell L.
author_role author
author2 Thompson, Ale J.
Flisiak, Robert
Romero Gómez, Manuel
Messinger, Diethelm
Bakalos, Georgios
Shiffman, Mitchell L.
author2_role author
author
author
author
author
author
dc.contributor.none.fl_str_mv Medicina
dc.subject.none.fl_str_mv HCV
Genotype 3
Peginterferon Alfa-2a/Ribavirin
topic HCV
Genotype 3
Peginterferon Alfa-2a/Ribavirin
description Background Access to direct-acting antiviral agents (DAAs) is restricted in some settings; thus, the Euro pean Association for the Study of the Liver recommends dual peginterferon/ribavirin (PegIFN/RBV) therapy wherever DAAs are unavailable. HCV genotype (GT) 3 infection is now the most difficult genotype to eradicate and PegIFN/RBV remains an effective option. The goal of this study was to devise a simple predictive score to identify GT3 patients with a high probability of achieving a sustained virologic response (SVR) with PegIFN alfa-2a/RBV therapy. Methods Relationships between baseline characteristics and SVR were explored by multiple logistic regression models and used to develop a simple scoring system to predict SVR using data from 1239 treatment-naive GT3 patients who received PegIFN alfa-2a/RBV for 24 weeks in two large observational cohort studies. Results The score was validated using a database of 473 patients. Scores were assigned for six fac tors as follows: age (years) ( 40: 2 points; >40 but 55: 1); bodyweight (kg) (<70: 2; 70 but <90: 1); no cirrhosis/transition to cirrhosis (2); ALT 2.5 x ULN (1); platelets (109 /L) (>200: 2; 100 but <200: 1); HCV RNA (<400,000 IU/mL: 1). The points are summed to arrive at a score ranging from 0-10 where higher scores indicate higher chances of SVR; 141, 123, 203, 249, 232, and 218 patients had total scores of 0-4, 5, 6, 7, 8, and 9–10, respectively, among whom SVR rates were 45%, 62%, 72%, 76%, 84%, and 89%. Among 622 patients who had scores of 6-10 and HCV RNA <50 IU/mL by treatment week 4 the SVR rate was 86% (532/622).
publishDate 2016
dc.date.none.fl_str_mv 2016
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/11441/108574
https://doi.org/10.1371/journal.pone.0150569
url https://hdl.handle.net/11441/108574
https://doi.org/10.1371/journal.pone.0150569
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv PLoS ONE, 11 (3)
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.source.none.fl_str_mv reponame:idUS. Depósito de Investigación de la Universidad de Sevilla
instname:Universidad de Sevilla (US)
instname_str Universidad de Sevilla (US)
reponame_str idUS. Depósito de Investigación de la Universidad de Sevilla
collection idUS. Depósito de Investigación de la Universidad de Sevilla
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869414747124793344
score 15,301629

Registos relacionados